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We propose that human adenoviruses (HAdVs) be identified, 
characterized, and typed on the basis of complete genome sequence 
analyses rather than serological approaches. This idea has recently 
percolated through the community of adenovirologists. As a result, an 
open-floor discussion took place at the Ninth International Adenovirus 
Meeting (Dobogókő, Hungary, April 2009) on the need for a paradigm shift 
in recognizing and naming HAdVs in the future. An ad hoc committee then 
met to formulate the principles of the new approach. Recommendations 1 
through 4 originated during the open-floor discussion and were discussed 
by the committee; recommendations 5 and 6 were developed by the 
authors to avoid conflicting claims and to deal with recombinants. These 
were reaffirmed at an NIH-sponsored and user-driven workshop of the 
Human Adenovirus Working Group, which met at NCBI (Bethesda, MD) on 
February 3, 2011.
“Type” will succeed “serotype,” reflecting the prevalence of genome 
sequence data usage; type is already in usage per International 
Committee on Taxonomy of Viruses (ICTV) definitions.
Previously named HAdVs will transition to the new format; e.g., “serotype 
HAdV-C1” will become “type HAdV-C1,” where the letter “C” 
indicates the adenovirus species (currently species A through G). 
Each adenovirus type will have a unique, consecutively assigned 
number; i.e., there will not be an HAdV-D54 and an HAdV-C54.
Acceptance of a new type will require analysis of the complete genome 
sequence, including phylogenomics.
Serum neutralization will continue to be used as an additional criterion, per 
the ICTV definition. This should be by actual serum neutralization 
and hemagglutination inhibition, rather than by imputed derivation by 
limited DNA sequencing of the epitopes.
Naming priority will follow the order in which genome sequence data are 
released in the public sequence databases. Adherence to the 
Bermuda principles, whereby sequences are released as soon as 
possible, will be encouraged (see http://www.ornl.gov/sci/
techresources/Human_Genome/publicat/hgn/v7n6/19intern.shtml).
Recombination is an accepted feature of HAdV evolution and will be 
accommodated. Recombinants will be classified as novel types if 
there are sufficient genomic, biological, or pathogenic differences 
from related types. Until a new recombinant genome is peer-
reviewed and published, a provisional standardized name that 
reflects critical serological markers and similarities to established 
types in species, penton base, and serology-based motifs in hexon 
and fiber, plus the year and place of isolation, will be used for the 
recombinant. Thus, the provisional name for HAdV-D53 is HAdV-D/
Hannover/[unique identifier]/2005/P37/H22/F8. “P” refers to the 
penton base, “H” to the hexon loop 1 region, and “F” to the fiber 
knob; numbers refer to the established type with the highest level of 
nucleotide identity in the respective regions. The unique identifier is 
a lab designation or strain name, e.g., 2005-IAI-1 for HAdV-D53 
isolate 1 and 2005-IAI-2 for HAdV-D53 isolate 2 should both 
genomes be deposited in GenBank.
Discoverers of “candidate” novel HAdV types should submit a FASTA file 
with the genome nucleotide sequence and the “evidence” to 
genomes@ncbi.nlm.nih.gov with the subject line “Human Adenovirus 
Working Group.” This file will be forwarded with submitter information 
removed to the NIH Human Adenovirus Working Group for a rapid, 
preliminary, confidential data review to coordinate the assignment of type 
number. This is not meant as a peer review but will prevent multiple 
genomes being assigned the same type number. Detailed information, 
including contact information for the working group members and current 
recommendations on typing parameters, may be found at http://
hadvwg.gmu.edu. HAdV typing criteria are being refined, and input from 
the community is appreciated.
Revisions to the criteria used in establishing HAdV types must avoid 
compromising the stability and utility of the current system while 
accommodating changes in technology that reflect the nature of the data 
available. The effective replacement of serology by DNA sequencing and 
bioinformatics has recently been observed with the characterization of 
HAdV-G52, HAdV-D53, HAdV-D54, HAdV-B55, and HAdV-D56. These 
advances set the scene for the recognition of new HAdV types in the 
future.
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